ACP
RNAC icon

Acuta Capital Partners’s Cartesian Therapeutics RNAC Stock Holding History

Acuta Capital Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34,156
Closed -$4.26M – 51
2021
Q3 		$4.26M Hold
34,156
– – 1.5% 18
2021
Q2 		$4.28M Buy
34,156
+6,723
+25% +$801K 1.71% 20
2021
Q1 		$3.72M Buy
+27,433
New +$3.41M 1.34% 32
2020
Q4 		– Sell
-78,807
Closed -$5.86M – 56
2020
Q3 		$5.86M Hold
78,807
– – 1.59% 23
2020
Q2 		$6.71M Hold
78,807
– – 1.94% 20
2020
Q1 		$5.7M Hold
78,807
– – 2.76% 14
2019
Q4 		$5.34M Buy
+78,807
New +$3.8M 1.32% 21

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's RNAC Position: Q4 2021 in Review

Acuta Capital Partners sold out of Cartesian Therapeutics (RNAC) in Q4 2021, closing a stake of 34,156 shares — an estimated $4.26M sold.

Acuta Capital Partners first reported a position in RNAC in Q4 2019 and held it in 7 quarters. The position peaked at $6.71M in Q2 2020. 106 funds tracked by Wall St. Rank hold RNAC as of Q4 2021.

  • Acuta Capital Partners reported no remaining Cartesian Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 34,156 Cartesian Therapeutics shares in Q4 2021, an estimated $4.26M.
  • Acuta Capital Partners first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 7 quarters.
  • Acuta Capital Partners's Cartesian Therapeutics position peaked at $6.71M in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.